Plasminogen deficiency
Methodology & AI Transparency ⓘ
Plasminogen deficiency Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Plasminogen deficiency (ICD-10-CM E88.02), Weight Management & Metabolic Syndrome protocols prioritize body composition DEXA in Plasminogen deficiency (E88.02: or waist-circumference anthropometry) paired with baseline and interval Waist-to-Height Ratio [Plasminogen deficiency E88.02] assessment.
- 2 Real-world patient consensus: Federal ICD-10-CM code E88.02 categorizes Plasminogen deficiency under Weight Management & Metabolic Syndrome.
- 3 Typical cash cost range: Clinicians assessing Plasminogen deficiency focus on hypothalamic arcuate nucleus in Plasminogen deficiency (E88.02: leptin resistance) and targeted history.
- 4 Top reported side effects / signs: Key Weight & Metabolism biomarkers for Plasminogen deficiency (E88.02): Waist-to-Height Ratio [Plasminogen deficiency E88.02] & HOMA-IR Insulin Resistance in Plasminogen deficiency (E88.02: Index) (< 1.4 (E88.02)).
Ask our AI Specialists anything about Plasminogen deficiency
What Is Plasminogen deficiency?
For patients presenting with Plasminogen deficiency (ICD-10-CM E88.02), Weight Management & Metabolic Syndrome protocols prioritize body composition DEXA in Plasminogen deficiency (E88.02: or waist-circumference anthropometry) paired with baseline and interval Waist-to-Height Ratio [Plasminogen deficiency E88.02] assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Plasminogen deficiency (E88.02) alters weight & metabolism homeostasis through hypothalamic arcuate nucleus in Plasminogen deficiency (E88.02: leptin resistance); clinical remission targets HOMA-IR Insulin Resistance in Plasminogen deficiency (E88.02: Index) within < 1.4 (E88.02).
Common Symptoms & Clinical Signs
- • Presentation of Plasminogen deficiency (E88.02): joint load discomfort in Plasminogen deficiency (E88.02: in knees, hips,)
- • Secondary Plasminogen deficiency clinical sign: daytime sluggishness or in Plasminogen deficiency (E88.02: loud snoring linked)
- • Symptom flares in Plasminogen deficiency correlating with Waist-to-Height Ratio [Plasminogen deficiency E88.02] deviation outside < 0.50 (E88.02)
- • Functional weight & metabolism impact requiring body composition DEXA in Plasminogen deficiency (E88.02: or waist-circumference anthropometry) evaluation (E88.02)
Plasminogen deficiency Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E88.02 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NLM Clinical Tables |
| Diagnostic / Lab Marker: Waist-to-Height Ratio [Plasminogen deficiency E88.02] | < 0.50 (E88.02) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HOMA-IR Insulin Resistance in Plasminogen deficiency (E88.02: Index) | < 1.4 (E88.02) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ALT & Fasting in Plasminogen deficiency (E88.02: Triglycerides) | ALT < 25 U/L; TG < 100 mg/dL (E88.02) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Plasminogen deficiency
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Tenecteplase Tnkase • RxCUI 284422 | FDA Prescription Therapeutic Agent | 92% | $2.0600 | $ 91.93 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Plasminogen deficiency)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature: What a 1,250,717-Participant Study Found This meta-analysis is the first to investigate the effects of GLP-1 RAs on a large panel of musculoskeletal health outcomes. Drugs • 2026-10-15 • Meta-Analysis | N = 1,250,717 | 99/100 | PMID 42730869 ↗ |
| New Insights on Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss: What a 902-Participant Study Found Among 803 study participants who completed the 20-week run-in period (with a mean weight loss of 10.6%) and were randomized (mean age, 46 [SD, 12] years; 634 [79%] women; mean body weight, 107.2 kg [SD, 22.7 kg]), 787... JAMA • 2021-04-13 • Phase III Randomized Trial | N = 902 | 93/100 | PMID 33755728 ↗ |
| What the Latest Evidence Really Says About Glucagon-like peptide-1 receptor agonists in adolescents with overweight or The evidence suggests that GLP-1RAs reduce most weight-related outcomes in adolescents, with semaglutide being the most efficacious. Diabetes, obesity & metabolism • 2024-10-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 39044306 ↗ |
| Can This Approach Help? Inside the Latest Research on Semaglutide and Taste in Women With Obesity and Polycystic Ovary Syndrome: A In women with obesity and PCOS, semaglutide improved an overall taste recognition score, altered RNA expression in the tongue and modified brain activity in response to sweet and savory food cues and to tasting sweet solution. The Journal of clinical endocrinology and metabolism • 2025-12-18 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 40341357 ↗ |
| Can This Approach Help? Inside the Latest Research on Clinical characteristics affecting weight loss in an East Asian population Semaglutide reduces BW in a wide demographic of people with a range of weight-related comorbidities in an East Asian population. Obesity research & clinical practice • 2024-01-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 39824696 ↗ |
Plasminogen deficiency Patient Community & “People Like Me” Threads
Filter Plasminogen deficiency community threads and patient logs by age, biological sex, dosage, and treatment duration.